Heart Failure Clinical Trial

A Study of Ultra High Dose Diuretics to Treat Heart Failure

Summary

The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of decompensated heart failure receiving intravenous diuretics
Ability to provide informed consent

Exclusion Criteria:

Patients on home inotrope medications
Patients with Chronic Kidney disease stage V and end stage renal failure on dialysis
Patients lacking the capacity to consent for themselves
Known pregnancy or breastfeeding mothers
Complex congenital heart disease
Allergy to furosemide or bumetanide
Respiratory failure requiring non-invasive ventilation (CPAP/BiPAP) or invasive mechanical ventilatory support at the time of randomization
Hypotension with systolic blood pressure <80 mm Hg at the time of randomization
Acute coronary syndrome
Sustained Ventricular tachycardia requiring treatment in the last 48 hours
Patients weighing ≤ 40 kg

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

20

Study ID:

NCT06036914

Recruitment Status:

Enrolling by invitation

Sponsor:

Mayo Clinic

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

20

Study ID:

NCT06036914

Recruitment Status:

Enrolling by invitation

Sponsor:


Mayo Clinic

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.